Archives of the Turkish Society of Cardiology
The impact of addressing modifiable risk factors to reduce the burden of cardiovascular disease in Turkey [Turk Kardiyol Dern Ars]
Turk Kardiyol Dern Ars. Ahead of Print: TKDA-40330 | DOI: 10.5543/tkda.2019.40330

The impact of addressing modifiable risk factors to reduce the burden of cardiovascular disease in Turkey

Yücel Balbay1, Isabelle Gagnon-Arpin2, Simten Malhan3, Mehmet Ergun Öksüz3, Greg Sutherland2, Alexandru Dobrescu2, Guillermo Villa4, Gülnihal Ertuğul5, Mohdhar Habib6
1University of Health Sciences, Ankara Yüksek Ihtisas Training and Research Hospital, Ankara, Turkey
2The Conference Board of Canada, Ottawa, Ontario, Canada
3Sağlık Yönetimi Programı, Baskent University, Ankara, Turkey
4Economic Modeling Center, Global Health Economics, Amgen Economic Modeling Center of Excellence, Zug, Switzerland
5Health Policy and Reimbursement, Amgen, Istanbul, Turkey
6Value, Access and Policy, Amgen, Inc, Thousand Oaks, California, United States of America


OBJECTIVE
Our study aimed to estimate the impact of addressing modifiable risk factors on the future burden of cardiovascular diseases (CVD) in the general population and in two high-risk populations (heterozygous familial hypercholesterolemia and secondary prevention) for Turkey.


METHODS
One model investigated the impact of reaching World Health Organization (WHO) voluntary targets for tobacco use, hypertension, type 2 diabetes, obesity and physical inactivity in the general population. Another model estimated the impact of reducing LDL-cholesterol in two high-risk populations through increased access to effective treatment. Inputs for the models include disease and risk factor prevalence rates, a population forecast, baseline CVD event rates, and treatment effectiveness, primarily derived from the published literature. Direct costs to the public health care system and indirect costs from lost production are included, although the cost of programs and pharmacological interventions to reduce risk factors was not considered.


RESULTS
The value of reaching WHO risk factor reduction targets is estimated at US$9.3 billion over the next 20 years, while the value of reducing LDL-cholesterol is estimated at up to US$8.1 billion for high-risk secondary prevention patients and US$691 million for heterozygous familial hypercholesterolemia patients.


CONCLUSION
Efforts to achieve WHO risk factor targets and further lower LDL-cholesterol through increased access to treatment for high-risk patients are projected to greatly reduce the growing clinical and economic burden of CVD in Turkey.

Keywords: Cardiovascular Diseases, Heart Diseases, Risk Factors, Hyperlipidemias, Public Health

How to cite this article


Corresponding Author: Yücel Balbay, Türkiye
© Copyright 2019 Archives of the Turkish Society of Cardiology
LookUs & Online Makale